Os therapies announces statistically significant positive final 2-year overall survival data from phase 2b trial of ost-her2 in the prevention or delay of recurrent, fully-resected, pulmonary metastatic osteosarcoma

75% of ost-her2 treated patients achieved 2-year overall survival compared with 40% in the historical control group (p < 0.0001) 100% of patients who achieved 12 month event free survival achieved 2 year overall survival new york, new york--(newsfile corp. - october 10, 2025) - os therapies inc. (nyse american: ostx) ("os therapies" or "the company"), a clinical-stage cancer immunotherapy and antibody drug conjugate biotechnology company, today announced statistically significant positive final 2-year overall survival data from the company's phase 2b trial of off-the-shelf immunotherapy candidate ost-her2 in the prevention or delay of recurrent, fully-resected, pulmonary metastatic osteosarcoma (the "fully resected metastatic osteosarcoma trial"). 75% (27 out of 36 evaluable patients; 5 patients were lost to follow-up) of ost-her2 treated patients achieved 2-year overall survival as measured from most recent pulmonary resection, compared with 40% of historical control patients1 (p < 0.0001) subgroup analyses showed that 100% of patients who achieved 12-month event free survival (efs) achieved 2-year overall survival, whereas 59% of patients who did not achieve efs achieved 2-year overall survival.
OST Ratings Summary
OST Quant Ranking